<!DOCTYPE html>
<html lang="en-US"><head>
		<meta charset="UTF-8">
		<title>FR940617-1-00034</title>
	</head>
	<body>
		<main>
			<p><!-- PJG STAG 4702 -->  <!-- PJG ITAG l=11 g=1 f=1 --> In addition, some products will have to be reformulated to  <!-- PJG 0012 frnewline --> comply with the monograph. Reformulation often involves the need  <!-- PJG 0012 frnewline --> to do stability testing on the new product. An accelerated aging  <!-- PJG 0012 frnewline --> process may be used to test a new formulation; however, if the  <!-- PJG 0012 frnewline --> stability testing is not successful, and if further reformulation  <!-- PJG 0012 frnewline --> is required, there could be a further delay in having a new  <!-- PJG 0012 frnewline --> product available for manufacture. The agency wishes to  <!-- PJG 0012 frnewline --> establish a reasonable period of time for relabeling and  <!-- PJG 0012 frnewline --> reformulation in order to avoid an unnecessary disruption of the  <!-- PJG 0012 frnewline --> marketplace that could not only result in economic loss, but also  <!-- PJG 0012 frnewline --> interfere with consumers' access to safe and effective drug  <!-- PJG 0012 frnewline --> products. Therefore, the agency is proposing that the final  <!-- PJG 0012 frnewline --> monograph be effective 12 months after the date of its publication in the  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=4 --> Federal Register <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> . The agency believes that  <!-- PJG 0012 frnewline --> within 12 months after the date of publication most manufacturers  <!-- PJG 0012 frnewline --> can order new labeling and reformulate their products and have  <!-- PJG 0012 frnewline --> them in compliance in the marketplace. If the agency determines  <!-- PJG 0012 frnewline --> that any labeling for a condition included in the final monograph  <!-- PJG 0012 frnewline --> should be implemented sooner than the 12-month effective date, a  <!-- PJG 0012 frnewline --> shorter deadline may be established. Similarly, if a safety  <!-- PJG 0012 frnewline --> problem is identified for a particular nonmonograph condition, a  <!-- PJG 0012 frnewline --> shorter deadline may be set for removal of that condition from  <!-- PJG 0012 frnewline --> OTC drug products.  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> All ``OTC Volumes'' cited throughout this document refer to  <!-- PJG 0012 frnewline --> the submissions made by interested persons pursuant to the  <!-- PJG 0012 frnewline --> call-for-data notice published in the  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=4 --> Federal Register <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->  of  <!-- PJG 0012 frnewline --> January 7, 1972 (37 FR 235) or to additional information that has  <!-- PJG 0012 frnewline --> come to the agency's attention since publication of the advance  <!-- PJG 0012 frnewline --> notice of proposed rulemaking. The volumes are on public display  <!-- PJG 0012 frnewline --> in the Dockets Management Branch (address above).  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=84 g=1 f=1 --> I. The Agency's Tentative Conclusions on the Comments and Reply Comments <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=83 g=1 f=1 --> A. General Comments  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> 1. Two comments contended that OTC drug monographs are  <!-- PJG 0012 frnewline --> interpretive, as opposed to substantive, regulations. One  <!-- PJG 0012 frnewline --> comment referred to statements on this issue submitted earlier to  <!-- PJG 0012 frnewline --> other OTC drug rulemaking proceedings.  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> The agency addressed this issue in paragraphs 85 through 91  <!-- PJG 0012 frnewline --> of the preamble to the procedures for classification of OTC drug products, published in the  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=4 --> Federal Register <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->  of May 11, 1972 (37  <!-- PJG 0012 frnewline --> FR 9464 at 9471 to 9472), and in paragraph 3 of the preamble to  <!-- PJG 0012 frnewline --> the tentative final monograph for OTC antacid drug products,  <!-- PJG 0012 frnewline --> published in the  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=4 --> Federal Register <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->  of November 12, 1973 (38 FR  <!-- PJG 0012 frnewline --> 31260). FDA reaffirms the conclusions stated in those documents.  <!-- PJG 0012 frnewline --> Court decisions have confirmed the agency's authority to issue  <!-- PJG 0012 frnewline --> substantive regulations by rulemaking. (See, e.g.,  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> National  <!-- PJG 0012 frnewline --> Nutritional Foods Association  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> v.  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Weinberger,  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> 512 F.2d 688, 696 to  <!-- PJG 0012 frnewline --> 698 (2d Cir. 1975) and  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> National Association of Pharmaceutical  <!-- PJG 0012 frnewline --> Manufacturers  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> v.  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> FDA,  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> 487 F. Supp. 412 (S.D.N.Y. 1980), aff'd,  <!-- PJG 0012 frnewline --> 637 F.2d 887 (2d Cir. 1981).)  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> 2. One comment pointed out that under ``Subpart B_Active  <!-- PJG 0012 frnewline --> Ingredients'' of the tentative final monograph, no CFR part number  <!-- PJG 0012 frnewline --> was assigned to the category ``skin antiseptic.'' However, part  <!-- PJG 0012 frnewline --> numbers were assigned to other categories without any Category I  <!-- PJG 0012 frnewline --> ingredients, with the term ``reserved'' in parentheses. The  <!-- PJG 0012 frnewline --> comment requested that this omission be corrected in the amended  <!-- PJG 0012 frnewline --> tentative final monograph.  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> The omission pointed out by the comment was an oversight.  <!-- PJG 0012 frnewline --> However, it is no longer necessary to assign a CFR part number to  <!-- PJG 0012 frnewline --> the category ``skin antiseptic,'' because skin antiseptics have  <!-- PJG 0012 frnewline --> been included in broader categories identified as first aid  <!-- PJG 0012 frnewline --> antiseptics in the amended tentative final monograph for first  <!-- PJG 0012 frnewline --> aid antiseptics (56 FR 33644) and as health-care antiseptics in  <!-- PJG 0012 frnewline --> this tentative final monograph. (See section I.B., comment 3.)  <!-- PJG 0012 frnewline --> All Category I first aid antiseptic and health-care antiseptic  <!-- PJG 0012 frnewline --> active ingredients have been listed in the amended tentative  <!-- PJG 0012 frnewline --> final monograph under subpart A and subpart E, respectively.  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=83 g=1 f=1 --> B. General Comments on Antimicrobials  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> 3. A number of comments objected to the Panel's  <!-- PJG 0012 frnewline --> recommendation for separate statements of identity in the  <!-- PJG 0012 frnewline --> labeling of products containing the same antimicrobial active  <!-- PJG 0012 frnewline --> ingredient. As an example, several comments noted that  <!-- PJG 0012 frnewline --> povidone-iodine has several professional uses (health-care  <!-- PJG 0012 frnewline --> personnel handwash, skin antiseptic, and surgical hand scrub) and  <!-- PJG 0012 frnewline --> marketing a product in conformance with two or more product  <!-- PJG 0012 frnewline --> categories becomes difficult because there are different labeling  <!-- PJG 0012 frnewline --> requirements for each drug product category. Some comments  <!-- PJG 0012 frnewline --> requested FDA to combine the drug product category designations  <!-- PJG 0012 frnewline --> or to add a new multipurpose product category that allows the  <!-- PJG 0012 frnewline --> combining of labeling indications now included in several product  <!-- PJG 0012 frnewline --> categories. One comment specifically recommended that the agency  <!-- PJG 0012 frnewline --> consider changing product class designations and/or adding a new  <!-- PJG 0012 frnewline --> product class ``Multi Purpose Skin Prep'' or ``Skin Prep,'' with the  <!-- PJG 0012 frnewline --> indications for use including those listed under &sect;333.85  <!-- PJG 0012 frnewline --> (health-care personnel hand wash), &sect;333.87 (patient preoperative  <!-- PJG 0012 frnewline --> skin preparation), &sect;333.90 (skin antiseptic), and &sect;333.97  <!-- PJG 0012 frnewline --> (surgical hand scrub).  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> Another comment stated that the word ``skin'' was superfluous  <!-- PJG 0012 frnewline --> because all OTC antiseptics are intended only for use on the  <!-- PJG 0012 frnewline --> skin; still another comment contended that the statement of  <!-- PJG 0012 frnewline --> identity ``antiseptic'' is preferable to ``skin antiseptic'' because  <!-- PJG 0012 frnewline --> these products are used on cuts, scratches, and mucous membranes  <!-- PJG 0012 frnewline --> as well as skin.  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG /STAG --></p>
		</main>
</body></html>
            